📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,076
All-time analysed
43,619
Positive
6,746
Negative
92,864
Neutral
8,779
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
848 announcements match the current filters (relevance ≥ 5).
Triveni Turbine FY26 Revenue Up 12% to ₹20,097 Mn; Recommends 200% Final Dividend
Triveni Turbine reported a steady 12% growth in standalone revenue for FY26, reaching ₹20,097 million compared to ₹17,952 million in the previous year. The company recommended a final dividend of 200% (₹2 per share), reflecting strong cash flow and commitment to shareholder returns. While Profit After Tax for the year was ₹3,367 million, slightly lower than FY25 due to a high base and exceptional items, the operational performance remains robust. The board also ensured leadership continuity by re-appointing two key independent directors for five-year terms.
Key Highlights
Standalone revenue for FY26 grew 12% YoY to ₹20,097 million.
Recommended a final dividend of 200% (₹2 per share) with a record date of September 2, 2026.
Q4 FY26 revenue stood at ₹6,025 million, up from ₹4,904 million in the year-ago period.
Profit Before Tax (PBT) for FY26 was ₹4,546 million, including an exceptional loss of ₹157 million.
Re-appointed Vijay Kumar Thadani and Vipin Sondhi as Independent Directors for a second 5-year term.
👀 What to Watch
Investors should view the steady revenue growth and healthy dividend payout as signs of operational strength. The stock remains a solid hold for those seeking exposure to the industrial engineering sector with consistent yield.
Triveni Turbine FY26 Revenue Up 12% to ₹20,097 Million; 200% Final Dividend Declared
Triveni Turbine Limited reported a 12% growth in annual revenue for FY26, reaching ₹20,097 million compared to ₹17,952 million in FY25. While annual Profit After Tax (PAT) decreased to ₹3,367 million from ₹3,744 million due to a high base effect from previous exceptional items, Q4 revenue showed strong momentum, growing 23% YoY to ₹6,025 million. The board has recommended a final dividend of 200% (₹2 per share) and approved the re-appointment of two key independent directors for five-year terms. The company maintains a healthy balance sheet with an unmodified audit opinion.
Key Highlights
FY26 total revenue from operations rose 11.9% YoY to ₹20,097 million.
Recommended a final dividend of 200% (₹2 per equity share) with a record date of September 2, 2026.
Q4 FY26 revenue grew significantly by 22.8% YoY to ₹6,025 million.
Standalone Profit Before Tax (PBT) for the full year stood at ₹4,546 million.
Re-appointed Independent Directors Vijay Kumar Thadani and Vipin Sondhi for second 5-year terms starting late 2026/early 2027.
👀 What to Watch
Investors should view the strong top-line growth and consistent dividend payout as signs of operational strength. The slight dip in annual PAT is largely attributable to the absence of exceptional gains recorded in the previous year, making the underlying performance robust.
Triveni Turbine FY26 Revenue Up 12%, Recommends 200% Final Dividend and Re-appoints Directors
Triveni Turbine Limited reported a steady growth in annual revenue from operations, reaching ₹20,097 million in FY26 compared to ₹17,952 million in FY25. The company announced a final dividend of 200% (₹2 per share) for the fiscal year, with a record date set for September 2, 2026. Standalone Profit After Tax for the year stood at ₹3,367 million, while the Board also approved the re-appointment of two Independent Directors for second five-year terms to ensure governance continuity. The financial results were issued with an unmodified audit opinion, reflecting stable internal controls.
Key Highlights
Revenue from operations grew 11.9% YoY to ₹20,097 million for the full year ended March 31, 2026
Recommended a final dividend of 200% or ₹2 per equity share of face value ₹1 each
Standalone Profit After Tax (PAT) for FY26 recorded at ₹3,367 million
Re-appointment of Vijay Kumar Thadani and Vipin Sondhi as Independent Directors for 5-year terms
Fixed September 2, 2026, as the Record Date for dividend entitlement
👀 What to Watch
Investors should focus on the healthy 12% revenue growth and the attractive dividend yield. The continuity in the board's leadership and unmodified audit reports suggest strong corporate governance, making it a stable hold for long-term portfolios.
Triveni Turbine Recommends ₹2 Final Dividend; FY26 Revenue Grows 12% to ₹20,097 Million
Triveni Turbine Limited has recommended a final dividend of ₹2 per share (200% of face value) for the financial year 2025-26. The company reported a 12% year-on-year increase in annual revenue, reaching ₹20,097 million compared to ₹17,952 million in the previous year. However, annual Profit After Tax (PAT) decreased to ₹3,367 million from ₹3,744 million, largely impacted by a ₹157 million exceptional loss versus a ₹360 million gain in the prior year. The Board also approved the re-appointment of two Independent Directors for five-year terms.
Key Highlights
Recommended final dividend of ₹2 per equity share (200% of face value) for FY26.
Annual revenue from operations grew 12% YoY to ₹20,097 million.
Standalone Profit After Tax (PAT) for FY26 stood at ₹3,367 million.
Record date for dividend entitlement is fixed as September 2, 2026.
Re-appointed Vijay Kumar Thadani and Vipin Sondhi as Independent Directors for 5-year terms.
👀 What to Watch
Investors should ensure they hold shares by the record date of September 2, 2026, to qualify for the ₹2 dividend. While revenue growth remains steady, the slight dip in net profit due to exceptional items should be monitored in upcoming quarterly reports.
Triveni Turbine FY26 Revenue Up 12% to ₹20,097 Million; Recommends ₹2 Final Dividend
Triveni Turbine reported a 12% year-on-year growth in standalone revenue for FY26, reaching ₹20,097 million. However, standalone Profit After Tax (PAT) for the full year declined to ₹3,367 million from ₹3,744 million in the previous year, partly due to a swing in exceptional items. The Board has recommended a final dividend of ₹2 per share (200%), with the record date set for September 2, 2026. Management continuity is also signaled through the re-appointment of two Independent Directors for five-year terms.
Key Highlights
Standalone Revenue for FY26 grew 12% to ₹20,097 million compared to ₹17,952 million in FY25.
Standalone Profit After Tax (PAT) for FY26 stood at ₹3,367 million, down from ₹3,744 million in the prior year.
Recommended a final dividend of 200% (₹2 per share) for FY26 with a record date of September 2, 2026.
Q4 FY26 standalone revenue rose to ₹6,025 million, a significant increase from ₹4,904 million in Q4 FY25.
Exceptional items for FY26 resulted in a net charge of ₹157 million versus a gain of ₹360 million in FY25.
👀 What to Watch
Investors should monitor the impact of rising material costs on margins despite healthy revenue growth. The steady dividend payout and top-line expansion remain positive, but the decline in net profit warrants a closer look at consolidated performance.
BIL Vyapar Limited Schedules 11th Committee of Creditors Meeting for May 19, 2026
BIL Vyapar Limited, formerly known as Binani Industries Limited, has announced the 11th meeting of its Committee of Creditors (CoC) scheduled for May 19, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. This meeting is a critical step in the ongoing legal efforts to resolve the company's debt and determine its future viability. Equity shareholders should remain cautious as insolvency proceedings often result in significant restructuring or liquidation.
Key Highlights
11th meeting of the Committee of Creditors (CoC) to be held on May 19, 2026.
Company is currently under the Corporate Insolvency Resolution Process (CIRP).
Disclosure made pursuant to Regulation 30 and Para 16(g) of SEBI LODR Regulations.
BIL Vyapar Limited was formerly known as Binani Industries Limited (NSE: BILVYAPAR).
👀 What to Watch
Investors should exercise extreme caution as equity value is typically at high risk during insolvency proceedings. Monitor for updates regarding any approved resolution plans or liquidation orders.
Cantabil FY26 PAT Jumps 28% to ₹95.8 Cr; Total Store Count Reaches 652
Cantabil Retail India Limited delivered robust financial results for FY26, with annual revenue growing 18% to ₹852.6 crore and Profit After Tax (PAT) increasing by 28% to ₹95.8 crore. The company expanded its retail footprint significantly, adding 53 new stores during the year to reach a total of 652 stores across 308 cities. Operational metrics remained healthy, with Same Store Growth (SSG) at 5.24% and a 13.33% increase in annual volume. The company also maintained industry-leading return ratios, reporting an ROCE of 40.2% and ROE of 22.0% for the fiscal year.
Key Highlights
Annual Revenue from Operations grew by 18% YoY to ₹852.6 crore in FY26
Full-year PAT increased by 28% to ₹95.8 crore, with EBITDA margins improving to 31.0%
The company added 53 new stores in FY26, bringing the total retail area to 9.15 lakh sq. ft.
Volume growth for the year stood at 13.33% YoY, supported by a 5.24% SSG
Strong profitability metrics with ROCE at 40.2% and ROE at 22.0% for FY26
👀 What to Watch
Investors should view the consistent double-digit growth in revenue and profitability, coupled with aggressive store expansion and high return ratios, as a sign of strong execution. Monitor the sustainability of SSG and margins as the company continues its expansion into new cities.
Cantabil Reports Record FY26 Profit of ₹95.8 Cr, Up 28% YoY; EBITDA Margins Hit 31%
Cantabil Retail India Limited delivered a strong performance for FY26, with annual revenue growing 18% to ₹852.6 crores and PAT rising 28% to ₹95.8 crores. The company achieved an industry-leading EBITDA margin of 31.0%, up from 28.4% in the previous year, driven by operational efficiencies and scale. Q4 FY26 also showed robust growth, with a 30% increase in PAT to ₹29.2 crores. With a network of 652 stores and a healthy Same Store Sales Growth (SSSG) of 5.24%, the company continues to expand its footprint in the value fashion segment.
Key Highlights
Annual Revenue from Operations increased by 18% YoY to ₹852.6 crores in FY26.
EBITDA margins expanded significantly to 31.0% in FY26 compared to 28.4% in FY25.
Net Profit (PAT) for the full year reached a record ₹95.8 crores, a 28% growth over FY25.
Reported a healthy Same Store Sales Growth (SSSG) of 5.24% for the fiscal year.
Retail footprint expanded to 652 stores across India, covering 9.15 lakh sq. ft.
👀 What to Watch
Investors should take note of the significant margin expansion and consistent 26% PAT CAGR over five years as indicators of high operational efficiency. The stock remains a strong contender in the retail apparel space due to its robust store network and healthy SSSG.
Cantabil Retail FY26 Net Profit Jumps 28% to ₹95.75 Cr; Revenue Up 18% YoY
Cantabil Retail India Limited reported a strong financial performance for the year ended March 31, 2026, with annual revenue growing 18.2% to ₹852.55 crore. Net profit for the full year increased by 27.9% to ₹95.75 crore, while Q4 net profit specifically surged by 29.8% year-on-year to ₹29.23 crore. The company showed significant expansion in its retail footprint, evidenced by a 33% increase in Right-of-use assets to ₹485.30 crore. Despite higher finance and depreciation costs, the company maintained robust profitability and improved its annual EPS to ₹11.45.
Key Highlights
Annual Revenue from operations increased 18.2% YoY to ₹85,255.36 lakhs.
Full-year Net Profit after tax rose 27.9% to ₹9,575.30 lakhs from ₹7,486.31 lakhs in FY25.
Q4 FY26 Net Profit stood at ₹2,923.46 lakhs, a 29.8% growth compared to the same quarter last year.
Right-of-use assets grew significantly to ₹48,530.23 lakhs, indicating aggressive store network expansion.
Earnings Per Share (EPS) for the full year improved to ₹11.45 from ₹8.95 in the previous fiscal.
👀 What to Watch
The company's strong double-digit growth in both top and bottom lines suggests successful retail execution and expansion. Investors should monitor the impact of rising finance costs on future margins as the company continues to scale its physical store presence.
Hester Biosciences Q4 FY26 PAT Surges 174% Driven by Poultry Segment and Exceptional Gains
Hester Biosciences reported a strong performance for Q4 FY26, with standalone revenue growing 22% and PAT jumping 174% YoY. The Poultry Healthcare division was the primary growth engine, recording 41% growth in Q4, while the consolidated annual PAT doubled, partly aided by exceptional income from a stake sale in Texas Lifesciences. The company has successfully capitalized its new Fill-Finish and BSL-3 facilities and received licenses for the H9N2 Avian Influenza vaccine. Despite earlier delays in government tenders, the company executed the supply of 6.3 crore PPR vaccine doses in the final quarter.
Key Highlights
Standalone Q4 PAT increased by 174% YoY, while consolidated FY26 PAT grew by 100% to reach record levels.
Poultry Healthcare division revenue grew 41% in Q4 and 21% for the full financial year FY26.
Supplied 6.3 crore doses of PPR vaccine in Q4 FY26, signaling a recovery in the Animal Healthcare tender business.
Received marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine, targeting the private commercial market.
Capitalized new Fill-Finish and BSL-3 facilities to enhance drug product capacity and operational efficiency.
👀 What to Watch
Investors should focus on the company's transition toward higher-margin biologicals and the scaling of the H9N2 vaccine. The successful capacity expansion and recovery in tender execution provide a positive outlook for FY27.
IDBI Bank Board Approves Raising Up to ₹10,000 Crore via Infrastructure Bonds
IDBI Bank's Board of Directors has approved a proposal to raise up to ₹10,000 crore through the issuance of long-term rupee-denominated bonds. These funds are specifically designated for financing infrastructure projects and affordable housing. The capital will be raised in one or more tranches via private placement in the domestic market through March 31, 2027. This strategic move aims to strengthen the bank's long-term resource base and support credit growth in high-priority sectors.
Key Highlights
Approved issuance of Long Term Rupee denominated Bonds up to ₹10,000 crore
Funds earmarked for Infrastructure and Affordable Housing financing
Issuance to be conducted via private placement in the domestic market
Fundraising window extends until March 31, 2027
The move follows the Board Meeting held on May 16, 2026
👀 What to Watch
Investors should monitor the bank's ability to deploy this capital into high-yield infrastructure projects, which could improve long-term margins. The fundraise is a positive indicator of the bank's growth intentions in the housing and infra segments.
MobiKwik Turns Profitable in Q4 FY26 with ₹4.4 Cr PAT; Payments GMV Hits Record ₹52,400 Cr
One MobiKwik Systems achieved a significant financial turnaround in FY26, reporting back-to-back profitable quarters in the second half of the year. Q4 FY26 saw a PAT of ₹4.4 crore and an EBITDA of ₹17.4 crore, a massive swing from the previous year's losses. The company's payments GMV reached an all-time high of ₹52,400 crore in Q4, driven by UPI growth that outpaced the industry by 6.5x. Management is now pivoting towards four growth engines, including merchant payments and an NBFC license, aiming for a 10x scale-up in merchant revenue by FY28.
Key Highlights
Achieved Q4 FY26 PAT of ₹4.4 crore (₹8.1 crore excluding one-time wage code charges) and EBITDA of ₹17.4 crore.
Full-year FY26 EBITDA improved by ₹74.2 crore to reach near break-even at -₹5.2 crore.
Payments GMV grew 58% YoY to ₹52,400 crore, with customer-initiated UPI transactions growing 170% YoY.
Financial services gross margin reached a record 59% in Q4, with super-prime customer mix rising to 32%.
Targeting 10x revenue growth in offline merchant payments and 10x GMV for Zaakpay by FY28.
👀 What to Watch
Investors should view the shift to profitability and the focus on super-prime lending as a positive sign of sustainable growth. Monitor the progress of the NBFC license application and the execution of the 10x merchant payment scale-up targets.
SBI Reports Record FY26 Net Profit of 80,032 Crores with Strong Asset Quality
State Bank of India (SBI) delivered a robust performance for FY26, reporting a record net profit of 80,032 crores, up 12.88% YoY. The bank maintained a healthy domestic Net Interest Margin (NIM) of 3.03% and achieved a credit growth of 16.87%, significantly outpacing deposit growth of 11.03%. Asset quality remains at a multi-decade high with Gross NPA at 1.49% and Net NPA at 0.39%. Management has guided for 13-14% credit growth in FY27 while maintaining an ROA of over 1%.
Key Highlights
Record annual net profit of 80,032 crores with a Return on Equity (ROE) of 18.5% in Q4FY26.
Asset quality improved with Gross NPA at 1.49% and Net NPA at 0.39%, the lowest in two decades.
Credit growth was robust at 16.87% YoY, while the domestic Credit-Deposit (CD) ratio improved to 73.08%.
Capital Adequacy Ratio (CAR) strengthened to 15.4%, providing a 115 bps YoY improvement for future growth.
Digital transformation continues with YONO crossing 10 crore users and 66% of new savings accounts being opened digitally.
👀 What to Watch
Investors should take confidence in SBI's ability to maintain high asset quality and a Return on Assets (ROA) above 1% at such a large scale. The bank remains a preferred play in the Indian banking sector due to its strengthening liability franchise and digital leadership.
Hester Biosciences FY26 Consolidated Revenue Hits ₹332.6 Cr; PAT Surges to ₹57.5 Cr
Hester Biosciences reported a strong financial performance for FY 2025-26, with consolidated revenue reaching ₹332.60 crore. The company witnessed a significant recovery in profitability, with consolidated Profit After Tax (PAT) jumping to ₹57.48 crore from ₹21.17 crore in the previous fiscal year. Hester maintains a dominant 35% market share in the Indian poultry vaccine market and is the world's largest supplier of the PPR vaccine. The company is strategically diversifying, with the Animal Healthcare division now contributing 38% to consolidated revenue.
Key Highlights
Consolidated revenue grew to ₹332.60 crore in FY26 compared to ₹311.10 crore in FY25.
Consolidated PAT surged to ₹57.48 crore, a substantial increase from ₹21.17 crore in the prior year.
Maintains a 35% market share in the Indian poultry vaccine segment as the second-largest manufacturer.
Annual manufacturing capacity stands at 8.6 billion doses in India, 1.24 billion in Nepal, and 1.5 billion in Africa.
Animal Healthcare division's revenue contribution rose to 38% on a consolidated basis, up from 29% on a standalone basis.
👀 What to Watch
Investors should view the sharp turnaround in profitability and margin expansion as a positive sign of operational efficiency. The company's leading position in global vaccine banks and expansion into the Petcare segment provide long-term growth visibility.
Hester Biosciences: Promoters Ravin and Bela Gandhi Seek Reclassification of 9.45% Stake to Public
Hester Biosciences has received formal requests from two members of its promoter group, Mr. Ravin Gandhi and Ms. Bela Gandhi, to be reclassified as public shareholders. Mr. Ravin Gandhi holds a 4.74% stake (403,320 shares) and recently resigned from the Board, while Ms. Bela Gandhi holds a 4.71% stake (400,635 shares). Together, they represent 9.45% of the company's voting rights and have declared they no longer exercise management control or hold special rights. The company is now initiating the necessary regulatory steps under SEBI guidelines to process these requests.
Key Highlights
Mr. Ravin Gandhi (4.74% stake) and Ms. Bela Gandhi (4.71% stake) have applied for reclassification from 'Promoter' to 'Public' category.
The combined shareholding involved in the reclassification request totals 803,955 equity shares or 9.45% of the company.
Mr. Ravin Gandhi resigned from the Board of Directors effective May 12, 2026, to facilitate this transition.
Ms. Bela Gandhi confirmed she has had no involvement in company management for the last 12 years.
The reclassification is subject to approval from the company's shareholders and the stock exchanges under SEBI Regulation 31A.
👀 What to Watch
Investors should view this as a standard regulatory restructuring of shareholding; however, monitor if this leads to any future secondary market sales by these individuals once they are classified as public. The move does not impact the company's day-to-day operations or business fundamentals.
Hester Biosciences Reports FY26 Consolidated Revenue of ₹332.6 Cr; 35% Poultry Vaccine Market Share
Hester Biosciences reported a consolidated revenue of ₹332.60 crore for FY 2025-26, with a consolidated PAT of ₹28.83 crore. The company maintains a dominant position as India's second-largest poultry vaccine manufacturer with a 35% market share. Notably, standalone PAT was significantly higher at ₹52.10 crore, suggesting that international subsidiaries in Nepal and Africa are currently impacting overall group profitability. The company is strategically focusing on the Petcare segment and large-scale vaccine projects in Africa to drive future growth.
Key Highlights
Consolidated revenue reached ₹332.60 Cr in FY26, with Poultry Healthcare contributing 62% and Animal Healthcare 38%.
Standalone PAT stood at ₹52.10 Cr, while consolidated PAT was lower at ₹28.83 Cr due to subsidiary performance.
Maintains a 35% market share in the Indian poultry vaccine market and is the world's largest supplier of the PPR vaccine.
Total annual manufacturing capacity across India, Nepal, and Africa plants exceeds 11.3 billion doses.
Ongoing expansion into the Petcare division and the VITAL 2 project for ruminant vaccines in Kenya, Nigeria, and Tanzania.
👀 What to Watch
Investors should focus on the company's ability to improve the profitability of its African and Nepal subsidiaries to match its strong standalone performance. The dominant market share in poultry vaccines and entry into the high-margin Petcare segment are positive long-term indicators.
Hester Biosciences Q4 PAT Surges 174% to INR 26.38 Cr; Declares INR 11 Dividend
Hester Biosciences reported a robust performance for Q4 FY26, with standalone revenue growing 22% YoY to INR 93.71 crore. Net profit for the quarter saw a significant jump of 174% YoY to INR 26.38 crore, bolstered by an exceptional gain of INR 6.99 crore from a subsidiary sale. The Board has recommended a healthy dividend of INR 11 per share (110% of face value). The Poultry Healthcare segment continues to be the primary growth engine, while the company also confirmed the re-appointment of Ms. Priya Gandhi as Executive Director.
Key Highlights
Standalone Q4 FY26 PAT rose to INR 263.84 million from INR 96.35 million in the previous year's quarter.
Full-year FY26 PAT increased by 63.6% to INR 521.00 million compared to INR 318.42 million in FY25.
Recommended a final dividend of INR 11 per equity share (110%) for the financial year 2025-26.
Poultry Healthcare segment revenue grew 41% YoY in Q4 to INR 650.72 million.
Recorded an exceptional gain of INR 69.96 million in Q4 FY26 from the sale of investment in a subsidiary.
👀 What to Watch
Investors should take note of the significant margin improvement and the strong recovery in the poultry segment. The healthy dividend payout and profit growth make this a positive update for long-term shareholders.
Hester Biosciences Q4 Consolidated PAT Surges 974% YoY; Recommends INR 11 Dividend
Hester Biosciences reported a massive 974% year-on-year surge in consolidated Q4 PAT to INR 165.46 million, driven by a 22% increase in revenue and significant margin expansion. For the full year FY26, consolidated PAT nearly doubled to INR 574.84 million despite a modest 7% revenue growth, reflecting improved operational efficiency and product mix. The Board has recommended a dividend of INR 11 per share (110%), while the Poultry Healthcare division remains the primary growth engine with 41% Q4 growth. However, the Animal Healthcare division continues to face headwinds from delayed government programs, declining 6% in Q4.
Key Highlights
Consolidated Q4 PAT jumped 974% YoY to INR 165.46 million; Standalone Q4 PAT rose 174% to INR 263.84 million.
Board recommended a final dividend of INR 11 per equity share (110%) for the financial year 2025-26.
Poultry Healthcare division revenue grew 41% in Q4 FY26, while Animal Healthcare revenue declined 6% due to government program delays.
Consolidated EBITDA margins improved significantly to 36% in Q4 FY26 from 17% in the previous year's quarter.
Successfully received marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine during the quarter.
👀 What to Watch
The sharp recovery in profitability and strong dividend payout make this a positive result for shareholders. Investors should monitor the scale-up of the new BSL 3 facility and the recovery of the Animal Healthcare segment as government tenders resume.
Hester Biosciences Recommends ₹11 Dividend; FY26 PAT Surges 64% to ₹521 Million
Hester Biosciences has recommended a final dividend of ₹11 per share for FY26, representing a 110% payout on face value. The company reported a strong financial performance with annual standalone Profit After Tax (PAT) rising 64% to ₹521 million, driven by significant growth in the Poultry Healthcare segment. Quarterly performance was particularly robust, with Q4 PAT jumping to ₹263.84 million from ₹96.35 million in the previous year. Additionally, the board approved the re-appointment of Ms. Priya Gandhi as Executive Director for a three-year term.
Key Highlights
Recommended a final dividend of ₹11 per equity share (110%) for the financial year 2025-26.
Standalone annual Profit After Tax (PAT) increased by 63.6% YoY to ₹521 million.
Q4 FY26 Revenue from operations grew 22% YoY to ₹937.13 million compared to ₹766.72 million.
Poultry Healthcare segment revenue grew to ₹2,061.31 million in FY26 from ₹1,665.83 million in FY25.
Earnings Per Share (EPS) improved significantly to ₹61.24 for FY26 compared to ₹37.43 in FY25.
👀 What to Watch
Investors should consider the strong bottom-line growth and healthy dividend payout as a sign of improved operational efficiency. The significant jump in Q4 margins and Poultry segment growth makes this a positive development for long-term holders.
Hester Biosciences Q4 Net Profit Jumps 174% to ₹26.38 Cr; Declares ₹11 Dividend
Hester Biosciences reported a robust performance for Q4 FY26, with standalone revenue growing 22% YoY to ₹937.13 million. Net profit for the quarter surged 174% to ₹263.84 million, significantly bolstered by an exceptional gain of ₹69.96 million from the sale of a subsidiary. For the full year FY26, the company achieved a net profit of ₹521.00 million, a 64% increase over FY25. The Board has recommended a healthy dividend of ₹11 per share (110% of face value).
Key Highlights
Q4 FY26 Standalone Revenue rose 22.2% YoY to ₹937.13 million compared to ₹766.72 million.
Standalone Net Profit for Q4 surged to ₹263.84 million from ₹96.35 million in the previous year.
Recommended a final dividend of ₹11 per equity share for the financial year 2025-26.
Poultry Healthcare segment revenue grew 24% in FY26, reaching ₹2,061.31 million.
Full-year FY26 Earnings Per Share (EPS) increased to ₹61.24 from ₹37.43 in FY25.
👀 What to Watch
Investors should view the strong recovery in the poultry segment and the significant jump in annual profitability as positive indicators. The stock remains attractive for long-term investors given the consistent dividend payout and the operationalization of new BSL-3 facilities.
